Discover Grünenthal

11/24/2022

Aachen, Germany and Tokyo, Japan, 24 November 2022 – Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.

11/22/2022

Aachen, Germany, 22 November 2022 – Grünenthal today announced that Janneke van der Kamp will join Grünenthal as the new Chief Commercial Officer (CCO), effective 1 March 2023. Janneke van der Kamp joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe.

7/14/2022

Aachen, Germany, 14 July 2022 – Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced an agreement with Bayer AG to acquire NebidoTM, the well-known brand for the treatment of male hypogonadism and its associated brands for up to € 500 million. NebidoTM is the only long-acting injectable treatment for testosterone deficiency. The product is approved and successfully commercialized in over 80 countries. Patent protection exists until March 2024 in the EU and until May 2027 in the US. The brand is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. The acquisition is subject to customary closing conditions, including approval by the relevant competition authorities. Closing is expected to occur by the end of 2022.

7/7/2022

Aachen, Germany, 7 July 2022 – Grünenthal, Uniklinik RWTH Aachen and RWTH Aachen University announced a collaboration to advance the development of next-generation pain medicines. The collaboration involves the institutes of Dr Angelika Lampert, Professor of Physiology at the Uniklinik RWTH Aachen and Dr Marc Spehr, Lichtenberg-Professor for Chemosensation at the RWTH Aachen University. The partners strive to develop a range of translational research tools and humanised preclinical models to enhance target validation.

3/30/2022

Aachen, Germany, 30 March 2022 – Grünenthal, an international science-driven pharmaceutical company and a leader in pain therapy, has announced its full-year results for 2021. Net revenues reached €1.5 billion, an increase of 15 percent over 2020. Adjusted EBITDA reached €370 million, increasing by 10 percent compared to the prior year. Profitability was driven by robust sales growth, improved production efficiency, and strict cost management. Grünenthal's continued strong performance enabled the company to almost triple its adjusted EBITDA since 2017.

3/7/2022

Aachen, Germany, 7 March 2022 – Grünenthal, an international science-driven pharmaceutical company, announced that it has donated 400.000€ to the Red Cross to support humanitarian relief efforts in Ukraine and Eastern Europe. In addition, Grünenthal partners with Action Medeor and the University Hospital RWTH Aachen to provide urgently needed pain medication to the region. The first transport with medicine is set to leave Aachen this week.

Florian Dieckmann Head Global Communication

Florian Dieckmann

Head Global Communication


Grünenthal GmbH

52099 Aachen


Phone +49 241 569 2555

E-Mail Florian.Dieckmann@grunenthal.com

Fabia Kehren, Head External Communications and Editorial Management

Fabia Kehren

Head of External Communication and Editorial Management


Grünenthal GmbH

52099 Aachen


Phone +49 241 569-3269

E-Mail Fabia.Kehren@grunenthal.com